Physician profile
Maria Coimbra
NPI 1316188725
$7,183.71
in general payments reported to CMS, 2019-2025
24 companies · $568 in 2025
The $568 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.68 · 2020: $99.76 · 2021: $163 · 2022: $5,410 · 2023: $581 · 2024: $290 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $5,123.51 | 2022-2023 | Veozah |
| Novo Nordisk INC | $392.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $253.88 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Amgen INC. | $237.62 | 2022-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $235.63 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $179.01 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Corcept Therapeutics | $105.70 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $98.90 | 2023-2024 | Airsupra, Farxiga |
| Dexcom, INC. | $96.93 | 2024-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $66.55 | 2019-2021 | |
| Redhill Biopharma INC. | $62.63 | 2020-2023 | Talicia |
| Abbott Laboratories | $55.48 | 2021-2023 | Freestyle Libre 3 |
| Pfizer INC. | $52.65 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $39.13 | 2022-2023 | |
| Optinose US, INC. | $28.35 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.64 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.36 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.29 | 2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $19.00 | 2020 | |
| Acclarent, INC | $17.26 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.17 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $13.39 | 2021 | |
| Genentech USA, INC. | $12.62 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Coimbra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.